Systemic Therapy for Melanoma

Last updated June 3, 2022

Key Points

Key Points

  • The clinical burden associated with the treatment of melanoma has been increasing due to rising incidence in most countries worldwide.
  • Since 2011, nine new drugs have been approved for unresectable melanoma, along with four new approvals in the adjuvant setting.
  • Overall survival for melanoma is improving equally rapidly, with dramatic increases in long-term survival observed from administration of these new therapies.
  • Uveal melanoma has received a 2022 recommendation based on new trial data.

Treatment

...Neoadjuvant Systemic...

...Cutane...

...ation 1.No recommendation can be made for o...


...Adjuvant Systemic The...

...Resected (Stage II, III,...

...2.1Adjuvant pembrolizumab, nivolum...

Recommendation...

...h resected stage IIIA/B/C/D disease that is B...

...pilimumab and high-dose interferon are NOT rec...

...2.3For patients with resected stage IIIA/B/C/D...

...endation 2.4No recommendation can be made for or...

...commendation 2...

...resected stage IV melanoma should b...

Patients with resected stage IV melanom...


...Systemic Therapy Optio...

...Unresectabl...

...3.1For patients with BRAF wild type...

Recommendation 3.2For patients with B...

...ommendation 3.3After progression on anti-P...

...ion 3.4After progression on 1st line anti-PD1 th...

...mmendation 3.5For patients with injectable (c...

...Non...

...ation 4.2In the absence of additional data, the co...

...ommendation 4.3No recommendation for o...


...New Re...

...Uveal Melanoma...

....1.1Previously untreated HLA-A*02:01-positive pa...

...ndation 4.1.2For all patients with uve...


...ble dose/schedule details for recommended...


Table 2. Reasonable dose/schedule de...


...e doses/schedules considered reasonable at the t...


...believes that cancer clinical trials are vital t...